Trial Profile

A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Exenatide Implant

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exenatide (Primary) ; Exenatide; Semaglutide
Indications Obesity; Type 2 diabetes mellitus
Focus Adverse reactions; First in man; Pharmacokinetics
Acronyms LIBERATE-1
Sponsors Vivani Medical

Most Recent Events

23 Sep 2025 Status changed from active, no longer recruiting to completed.
05 Aug 2025 Results presented in a Vivani Medical media release.
10 Jun 2025 According to a Vivani Medical media release, results from LIBERATE-1, the first human clinical trial of NPM-115, are expected later this year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com